Annovis Bio, Inc. (ANVS) Form 10-Q — May 15, 2026
Annovis Bio reported a net loss of $17.6 million for the first quarter of 2026, driven by a sharp increase in R&D expenses to $16.7 million as it ramps up its pivotal Phase 3 Alzheimer’s trial. The company ended the quarter with $14.2 million in cash, which management explicitly stated is insufficient to fund operations for the next 12 months. Management has concluded that substantial doubt exists regarding the company’s ability to continue as a going concern, citing the need for additional capital to complete clinical development.
Key figures
- Total Debt
- 327000
- Total Assets
- 16243703
- Cash Position
- 14219081
- Shares Outstanding
- 28537302
- Rd expense q1 2025
- 5011517
- Rd expense q1 2026
- 16720362
- Gross proceeds atm q1
- 3800000
- Net proceeds canaccord april
- 9300000
- Gross proceeds canaccord april
- 10000000
Price after filing
Close on the filing date to close N calendar days later (from $2.13). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.